

SAFETY DATA SHEET



ViraPack Transfection Kit, Part Number 200488

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : ViraPack Transfection Kit, Part Number 200488
Part No. (Kit) : 200488
Part No. : ViraPack Transfection Kit Solution 1 200488-51
ViraPack Transfection Kit Solution 2 200488-52
Virapack Transfection Kit Solution 3 200488-53
pCMV β -Gal Control Plasmid 200388-54

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses	
Analytical reagent.	
ViraPack Transfection Kit Solution 1	5 ml
ViraPack Transfection Kit Solution 2	25 ml
Virapack Transfection Kit Solution 3	40 ml
pCMV β -Gal Control Plasmid	0.04 ml (40 μ g 1 μ g/ μ l)

1.3 Details of the supplier of the safety data sheet

Agilent Technologies Manufacturing GmbH & Co. KG
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000

e-mail address of person responsible for this SDS : pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation) : CHEMTREC®: +(44)-870-8200418

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : ViraPack Transfection Kit Solution 1 Mixture
ViraPack Transfection Kit Solution 2 Mixture
Virapack Transfection Kit Solution 3 Mixture
pCMV β -Gal Control Plasmid Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

ViraPack Transfection Kit

Solution 1

H319

SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2

Date of issue/Date of revision : 30/03/2017

SECTION 2: Hazards identification

Ingredients of unknown toxicity	: ViraPack Transfection Kit Solution 2	Percentage of the mixture consisting of ingredient(s) of unknown toxicity: 1.1%
	Virapack Transfection Kit Solution 3	Percentage of the mixture consisting of ingredient(s) of unknown toxicity: 98.8%
Ingredients of unknown ecotoxicity	: ViraPack Transfection Kit Solution 2	Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic environment: 1.1%
	Virapack Transfection Kit Solution 3	Percentage of the mixture consisting of ingredient(s) of unknown hazards to the aquatic environment: 98.8%

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms :



Signal word

: ViraPack Transfection Kit Solution 1	Warning
ViraPack Transfection Kit Solution 2	No signal word.
Virapack Transfection Kit Solution 3	No signal word.
pCMV β-Gal Control Plasmid	No signal word.

Hazard statements

: ViraPack Transfection Kit Solution 1	GHS07 - Causes serious eye irritation.
ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
pCMV β-Gal Control Plasmid	No known significant effects or critical hazards.

Precautionary statements

Prevention

: ViraPack Transfection Kit Solution 1	P280 - Wear eye or face protection.
ViraPack Transfection Kit Solution 2	P264 - Wash hands thoroughly after handling. Not applicable.
Virapack Transfection Kit Solution 3	Not applicable.
pCMV β-Gal Control Plasmid	Not applicable.

Response

: ViraPack Transfection Kit Solution 1	P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
ViraPack Transfection Kit Solution 2	Not applicable.
Virapack Transfection Kit Solution 3	Not applicable.
pCMV β-Gal Control Plasmid	Not applicable.

Storage

: ViraPack Transfection Kit Solution 1	Not applicable.
ViraPack Transfection Kit Solution 2	Not applicable.
Virapack Transfection Kit Solution 3	Not applicable.
pCMV β-Gal Control Plasmid	Not applicable.

SECTION 2: Hazards identification

Disposal	:	ViraPack Transfection Kit Solution 1	Not applicable.
		ViraPack Transfection Kit Solution 2	Not applicable.
		Virapack Transfection Kit Solution 3	Not applicable.
		pCMV β -Gal Control Plasmid	Not applicable.
Hazardous ingredients	:	ViraPack Transfection Kit Solution 1	Not applicable.
		ViraPack Transfection Kit Solution 2	Not applicable.
Supplemental label elements	:	ViraPack Transfection Kit Solution 1	Not applicable.
		ViraPack Transfection Kit Solution 2	Safety data sheet available on request.
		Virapack Transfection Kit Solution 3	Not applicable.
		pCMV β -Gal Control Plasmid	Not applicable.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	ViraPack Transfection Kit Solution 1	Not applicable.
		ViraPack Transfection Kit Solution 2	Not applicable.
		Virapack Transfection Kit Solution 3	Not applicable.
		pCMV β -Gal Control Plasmid	Not applicable.
<u>Special packaging requirements</u>			
Tactile warning of danger	:	ViraPack Transfection Kit Solution 1	Not applicable.
		ViraPack Transfection Kit Solution 2	Not applicable.
		Virapack Transfection Kit Solution 3	Not applicable.
		pCMV β -Gal Control Plasmid	Not applicable.
2.3 Other hazards			
Other hazards which do not result in classification	:	ViraPack Transfection Kit Solution 1	None known.
		ViraPack Transfection Kit Solution 2	None known.
		Virapack Transfection Kit Solution 3	None known.
		pCMV β -Gal Control Plasmid	None known.

SECTION 3: Composition/information on ingredients

3.1 Substances	:	ViraPack Transfection Kit Solution 1	Mixture
		ViraPack Transfection Kit Solution 2	Mixture
		Virapack Transfection Kit Solution 3	Mixture
		pCMV β -Gal Control Plasmid	Mixture

SECTION 3: Composition/information on ingredients

Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Type
ViraPack Transfection Kit Solution 1 Calcium chloride (CaCl ₂), dihydrate	EC: 233-140-8 CAS: 10035-04-8 Index: 017-013-00-2	≥25 - ≤50	Eye Irrit. 2, H319	[1]
ViraPack Transfection Kit Solution 2 Sodium chloride	EC: 231-598-3 CAS: 7647-14-5	≤3	Eye Irrit. 2, H319	[1]
2-[bis(2-Hydroxyethyl)amino] ethanesulphonic acid	EC: 233-465-5 CAS: 10191-18-1	≤3	Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335	[1]
Virapack Transfection Kit Solution 3 Ethanol	EC: 200-578-6 CAS: 64-17-5 Index: 603-002-00-5	≤3	Flam. Liq. 2, H225	[2]
			See Section 16 for the full text of the H statements declared above.	

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Type

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: ViraPack Transfection Kit Solution 1	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
	ViraPack Transfection Kit Solution 2	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
	Virapack Transfection Kit Solution 3	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
	pCMV β-Gal Control Plasmid	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
Inhalation	: ViraPack Transfection Kit Solution 1	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
	ViraPack Transfection	Remove victim to fresh air and keep at rest in a position

SECTION 4: First aid measures

	Kit Solution 2	comfortable for breathing. Get medical attention if symptoms occur. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
	Virapack Transfection Kit Solution 3	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
	pCMV β-Gal Control Plasmid	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
Skin contact	: ViraPack Transfection Kit Solution 1	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.
	ViraPack Transfection Kit Solution 2	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
	Virapack Transfection Kit Solution 3	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
	pCMV β-Gal Control Plasmid	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
Ingestion	: ViraPack Transfection Kit Solution 1	Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
	ViraPack Transfection Kit Solution 2	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
	Virapack Transfection Kit Solution 3	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
	pCMV β-Gal Control Plasmid	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
Protection of first-aiders	: ViraPack Transfection Kit Solution 1	No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.
	ViraPack Transfection Kit Solution 2	No action shall be taken involving any personal risk or without suitable training.
	Virapack Transfection Kit Solution 3	No action shall be taken involving any personal risk or without suitable training.

SECTION 4: First aid measurespCMV β -Gal Control
Plasmid

No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed**Potential acute health effects**

Eye contact	: ViraPack Transfection Kit Solution 1	Causes serious eye irritation.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Inhalation	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Skin contact	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Ingestion	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact	: ViraPack Transfection Kit Solution 1	Adverse symptoms may include the following: pain or irritation watering redness
	ViraPack Transfection Kit Solution 2	No specific data.
	Virapack Transfection Kit Solution 3	No specific data.
	pCMV β -Gal Control Plasmid	No specific data.
Inhalation	: ViraPack Transfection Kit Solution 1	No specific data.
	ViraPack Transfection Kit Solution 2	No specific data.
	Virapack Transfection Kit Solution 3	No specific data.
	pCMV β -Gal Control Plasmid	No specific data.

SECTION 4: First aid measures

Skin contact	: ViraPack Transfection Kit Solution 1	No specific data.
	ViraPack Transfection Kit Solution 2	No specific data.
	Virapack Transfection Kit Solution 3	No specific data.
	pCMV β -Gal Control Plasmid	No specific data.
Ingestion	: ViraPack Transfection Kit Solution 1	No specific data.
	ViraPack Transfection Kit Solution 2	No specific data.
	Virapack Transfection Kit Solution 3	No specific data.
	pCMV β -Gal Control Plasmid	No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	: ViraPack Transfection Kit Solution 1	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
	ViraPack Transfection Kit Solution 2	
	Virapack Transfection Kit Solution 3	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: pCMV β -Gal Control Plasmid	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
	: ViraPack Transfection Kit Solution 1	No specific treatment.
	ViraPack Transfection Kit Solution 2	No specific treatment.
	Virapack Transfection Kit Solution 3	No specific treatment.
	pCMV β -Gal Control Plasmid	No specific treatment.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

Suitable extinguishing media	: ViraPack Transfection Kit Solution 1	Use an extinguishing agent suitable for the surrounding fire.
	ViraPack Transfection Kit Solution 2	Use an extinguishing agent suitable for the surrounding fire.
	Virapack Transfection Kit Solution 3	Use an extinguishing agent suitable for the surrounding fire.
	pCMV β -Gal Control Plasmid	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: ViraPack Transfection Kit Solution 1	None known.
	ViraPack Transfection Kit Solution 2	None known.
	Virapack Transfection Kit Solution 3	None known.
	pCMV β -Gal Control Plasmid	None known.

5.2 Special hazards arising from the substance or mixture

SECTION 5: Firefighting measures

Hazards from the substance or mixture	: ViraPack Transfection Kit Solution 1 ViraPack Transfection Kit Solution 2 Virapack Transfection Kit Solution 3 pCMV β-Gal Control Plasmid	In a fire or if heated, a pressure increase will occur and the container may burst. In a fire or if heated, a pressure increase will occur and the container may burst. In a fire or if heated, a pressure increase will occur and the container may burst. In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	: ViraPack Transfection Kit Solution 1 ViraPack Transfection Kit Solution 2 Virapack Transfection Kit Solution 3 pCMV β-Gal Control Plasmid	Decomposition products may include the following materials: halogenated compounds metal oxide/oxides Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides sulfur oxides halogenated compounds metal oxide/oxides Decomposition products may include the following materials: carbon dioxide carbon monoxide No specific data.

5.3 Advice for firefighters

Special precautions for fire-fighters	: ViraPack Transfection Kit Solution 1 ViraPack Transfection Kit Solution 2 Virapack Transfection Kit Solution 3 pCMV β-Gal Control Plasmid	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	: ViraPack Transfection Kit Solution 1 ViraPack Transfection Kit Solution 2 Virapack Transfection Kit Solution 3 pCMV β-Gal Control Plasmid	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a

SECTION 5: Firefighting measures

basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	:	ViraPack Transfection Kit Solution 1	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
		ViraPack Transfection Kit Solution 2	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
		Virapack Transfection Kit Solution 3	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
		pCMV β -Gal Control Plasmid	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
For emergency responders	:	ViraPack Transfection Kit Solution 1	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
		ViraPack Transfection Kit Solution 2	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
		Virapack Transfection Kit Solution 3	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
		pCMV β -Gal Control Plasmid	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	ViraPack Transfection Kit Solution 1	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
		ViraPack Transfection Kit Solution 2	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
		Virapack Transfection Kit Solution 3	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
		pCMV β -Gal Control Plasmid	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

SECTION 6: Accidental release measures

Methods for cleaning up	: ViraPack Transfection Kit Solution 1	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
	ViraPack Transfection Kit Solution 2	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
	Virapack Transfection Kit Solution 3	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
	pCMV β -Gal Control Plasmid	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections : See Section 1 for emergency contact information.
 See Section 8 for information on appropriate personal protective equipment.
 See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures	: ViraPack Transfection Kit Solution 1	Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
	ViraPack Transfection Kit Solution 2	Put on appropriate personal protective equipment (see Section 8).
	Virapack Transfection Kit Solution 3	Put on appropriate personal protective equipment (see Section 8).
	pCMV β -Gal Control Plasmid	Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: ViraPack Transfection Kit Solution 1	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
	ViraPack Transfection Kit Solution 2	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
	Virapack Transfection Kit Solution 3	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
	pCMV β -Gal Control Plasmid	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also

SECTION 7: Handling and storage

Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Storage	: ViraPack Transfection Kit Solution 1	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
	ViraPack Transfection Kit Solution 2	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
	Virapack Transfection Kit Solution 3	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
	pCMV β -Gal Control Plasmid	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

7.3 Specific end use(s)

Recommendations	: ViraPack Transfection Kit Solution 1	Industrial applications, Professional applications.
	ViraPack Transfection Kit Solution 2	Industrial applications, Professional applications.
	Virapack Transfection Kit Solution 3	Industrial applications, Professional applications.
	pCMV β -Gal Control Plasmid	Industrial applications, Professional applications.
Industrial sector specific solutions	: ViraPack Transfection Kit Solution 1	Not applicable.
	ViraPack Transfection Kit Solution 2	Not applicable.
	Virapack Transfection Kit Solution 3	Not applicable.
	pCMV β -Gal Control Plasmid	Not applicable.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
Virapack Transfection Kit Solution 3 Ethanol	EH40/2005 WELs (United Kingdom (UK), 12/2011). TWA: 1000 ppm 8 hours. TWA: 1920 mg/m ³ 8 hours.

Recommended monitoring procedures : If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

No DNELs/DMELs available.

PNECs

No PNECs available

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

SECTION 8: Exposure controls/personal protection

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**Appearance

Physical state	:	ViraPack Transfection Kit Solution 1	Liquid.
		ViraPack Transfection Kit Solution 2	Liquid.
		Virapack Transfection Kit Solution 3	Liquid.
		pCMV β -Gal Control Plasmid	Liquid.
Colour	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Odour	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Odour threshold	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
pH	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	6.95
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Melting point/freezing point	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	0°C
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	0°C

SECTION 9: Physical and chemical properties

Initial boiling point and boiling range	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	100°C
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	100°C
Flash point	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	Not available.
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	Not available.
Evaporation rate	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	Not available.
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	Not available.
Flammability (solid, gas)	: ViraPack Transfection Kit Solution 1	Not applicable.
	ViraPack Transfection Kit Solution 2	Not applicable.
	Virapack Transfection Kit Solution 3	Not applicable.
	pCMV β -Gal Control Plasmid	Not applicable.
Upper/lower flammability or explosive limits	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	Not available.
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	Not available.
Vapour pressure	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	Not available.
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	Not available.
Vapour density	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	Not available.
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	Not available.

SECTION 9: Physical and chemical properties

Relative density	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Solubility(ies)	:	ViraPack Transfection Kit Solution 1	Soluble in the following materials: cold water and hot water.
		ViraPack Transfection Kit Solution 2	Easily soluble in the following materials: cold water and hot water.
		Virapack Transfection Kit Solution 3	Easily soluble in the following materials: cold water and hot water.
		pCMV β -Gal Control Plasmid	Easily soluble in the following materials: cold water and hot water.
Partition coefficient: n-octanol/water	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Auto-ignition temperature	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Decomposition temperature	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Viscosity	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.
Explosive properties	:	ViraPack Transfection Kit Solution 1	Not available.
		ViraPack Transfection Kit Solution 2	Not available.
		Virapack Transfection Kit Solution 3	Not available.
		pCMV β -Gal Control Plasmid	Not available.

SECTION 9: Physical and chemical properties

Oxidising properties	: ViraPack Transfection Kit Solution 1	Not available.
	ViraPack Transfection Kit Solution 2	Not available.
	Virapack Transfection Kit Solution 3	Not available.
	pCMV β -Gal Control Plasmid	Not available.

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity

10.1 Reactivity	: ViraPack Transfection Kit Solution 1	No specific test data related to reactivity available for this product or its ingredients.
	ViraPack Transfection Kit Solution 2	No specific test data related to reactivity available for this product or its ingredients.
	Virapack Transfection Kit Solution 3	No specific test data related to reactivity available for this product or its ingredients.
	pCMV β -Gal Control Plasmid	No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability	: ViraPack Transfection Kit Solution 1	The product is stable.
	ViraPack Transfection Kit Solution 2	The product is stable.
	Virapack Transfection Kit Solution 3	The product is stable.
	pCMV β -Gal Control Plasmid	The product is stable.

10.3 Possibility of hazardous reactions	: ViraPack Transfection Kit Solution 1	Under normal conditions of storage and use, hazardous reactions will not occur.
	ViraPack Transfection Kit Solution 2	Under normal conditions of storage and use, hazardous reactions will not occur.
	Virapack Transfection Kit Solution 3	Under normal conditions of storage and use, hazardous reactions will not occur.
	pCMV β -Gal Control Plasmid	Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid	: ViraPack Transfection Kit Solution 1	No specific data.
	ViraPack Transfection Kit Solution 2	No specific data.
	Virapack Transfection Kit Solution 3	No specific data.
	pCMV β -Gal Control Plasmid	No specific data.

10.5 Incompatible materials	: ViraPack Transfection Kit Solution 1	May react or be incompatible with oxidising materials.
	ViraPack Transfection Kit Solution 2	May react or be incompatible with oxidising materials.
	Virapack Transfection Kit Solution 3	May react or be incompatible with oxidising materials.
	pCMV β -Gal Control Plasmid	May react or be incompatible with oxidising materials.

SECTION 10: Stability and reactivity

10.6 Hazardous decomposition products	: ViraPack Transfection Kit Solution 1 ViraPack Transfection Kit Solution 2 Virapack Transfection Kit Solution 3 pCMV β -Gal Control Plasmid	Under normal conditions of storage and use, hazardous decomposition products should not be produced. Under normal conditions of storage and use, hazardous decomposition products should not be produced. Under normal conditions of storage and use, hazardous decomposition products should not be produced. Under normal conditions of storage and use, hazardous decomposition products should not be produced.
--	---	--

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
ViraPack Transfection Kit Solution 2 Sodium chloride	LD50 Oral	Rat	3000 mg/kg	-

Acute toxicity estimates

Not available.

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
ViraPack Transfection Kit Solution 2 Sodium chloride	Eyes - Moderate irritant	Rabbit	-	24 hours 100 milligrams	-
	Eyes - Moderate irritant	Rabbit	-	10 milligrams	-
	Skin - Mild irritant	Rabbit	-	24 hours 500 milligrams	-

Sensitiser

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
ViraPack Transfection Kit Solution 2 2-[bis(2-Hydroxyethyl)amino]ethanesulphonic acid	Category 3	Not applicable.	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes of exposure

: ViraPack Transfection Kit Solution 1	Routes of entry anticipated: Oral, Dermal, Inhalation.
ViraPack Transfection Kit Solution 2	Routes of entry anticipated: Oral, Dermal, Inhalation.
Virapack Transfection Kit Solution 3	Routes of entry anticipated: Oral, Dermal, Inhalation.
pCMV β -Gal Control Plasmid	Not available.

Potential acute health effects

SECTION 11: Toxicological information

Inhalation	:	ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
		ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
		Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
		pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Ingestion	:	ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
		ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
		Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
		pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Skin contact	:	ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
		ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
		Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
		pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Eye contact	:	ViraPack Transfection Kit Solution 1	Causes serious eye irritation.
		ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
		Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
		pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Inhalation	:	ViraPack Transfection Kit Solution 1	No specific data.
		ViraPack Transfection Kit Solution 2	No specific data.
		Virapack Transfection Kit Solution 3	No specific data.
		pCMV β -Gal Control Plasmid	No specific data.
Ingestion	:	ViraPack Transfection Kit Solution 1	No specific data.
		ViraPack Transfection Kit Solution 2	No specific data.
		Virapack Transfection Kit Solution 3	No specific data.
		pCMV β -Gal Control Plasmid	No specific data.
Skin contact	:	ViraPack Transfection Kit Solution 1	No specific data.
		ViraPack Transfection Kit Solution 2	No specific data.
		Virapack Transfection Kit Solution 3	No specific data.
		pCMV β -Gal Control Plasmid	No specific data.

SECTION 11: Toxicological information

Eye contact	: ViraPack Transfection Kit Solution 1	Adverse symptoms may include the following: pain or irritation watering redness
	ViraPack Transfection Kit Solution 2	No specific data.
	Virapack Transfection Kit Solution 3	No specific data.
	pCMV β -Gal Control Plasmid	No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

General	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Carcinogenicity	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Mutagenicity	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Teratogenicity	: ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
	ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
	Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
	pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.

SECTION 11: Toxicological information

Developmental effects	:	ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
		ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
		Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
		pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.
Fertility effects	:	ViraPack Transfection Kit Solution 1	No known significant effects or critical hazards.
		ViraPack Transfection Kit Solution 2	No known significant effects or critical hazards.
		Virapack Transfection Kit Solution 3	No known significant effects or critical hazards.
		pCMV β -Gal Control Plasmid	No known significant effects or critical hazards.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
ViraPack Transfection Kit Solution 1 Calcium chloride (CaCl ₂), dihydrate	Acute EC50 2900 mg/l Fresh water	Algae	72 hours
	Acute NOEC 2000 mg/l Fresh water	Daphnia	48 hours
ViraPack Transfection Kit Solution 2 Sodium chloride	Acute EC50 2430000 μ g/l Fresh water	Algae - Navicula seminulum	96 hours
	Acute EC50 28.85 mg/dm ³ Fresh water	Algae - Pseudokirchneriella subcapitata	72 hours
	Acute EC50 519.6 mg/l Fresh water	Crustaceans - Cypris subglobosa	48 hours
	Acute IC50 6.87 g/L Fresh water	Aquatic plants - Lemna minor	96 hours
	Acute LC50 1.56 g/L Fresh water	Daphnia - Daphnia magna	48 hours
	Acute LC50 1000000 μ g/l Fresh water	Fish - Morone saxatilis - Larvae	96 hours
	Chronic LC10 781 mg/l Fresh water	Crustaceans - Hyalella azteca - Juvenile (Fledgling, Hatchling, Weanling)	3 weeks
Chronic NOEC 6 g/L Fresh water	Aquatic plants - Lemna minor	96 hours	
Chronic NOEC 0.314 g/L Fresh water	Daphnia - Daphnia pulex	21 days	
Chronic NOEC 100 mg/l Fresh water	Fish - Gambusia holbrooki - Adult	8 weeks	

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

PBT : Not applicable.

SECTION 12: Ecological information

vPvB : Not applicable.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste : The classification of the product may meet the criteria for a hazardous waste.

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

Regulatory information

ADR/RID / IMDG / IATA : Not regulated.

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code : Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	ViraPack Transfection Kit Solution 1	Not applicable.
	ViraPack Transfection Kit Solution 2	Not applicable.
	Virapack Transfection Kit Solution 3	Not applicable.
	pCMV β-Gal Control Plasmid	Not applicable.

Other EU regulations

Europe inventory : Not determined.

Ozone depleting substances (1005/2009/EU)

Not listed.

SECTION 15: Regulatory information

[Prior Informed Consent \(PIC\) \(649/2012/EU\)](#)

Not listed.

[Seveso Directive](#)

This product is not controlled under the Seveso Directive.

[International regulations](#)

[Chemical Weapon Convention List Schedules I, II & III Chemicals](#)

Not listed.

[Montreal Protocol \(Annexes A, B, C, E\)](#)

Not listed.

[Stockholm Convention on Persistent Organic Pollutants](#)

Not listed.

[Rotterdam Convention on Prior Informed Consent \(PIC\)](#)

Not listed.

[UNECE Aarhus Protocol on POPs and Heavy Metals](#)

Not listed.


[International lists](#)

[National inventory](#)

Australia	: Not determined.
Canada	: Not determined.
China	: Not determined.
Japan	: Japan inventory (ENCS): Not determined. Japan inventory (ISHL): Not determined.
Malaysia	: Not determined.
New Zealand	: All components are listed or exempted.
Philippines	: Not determined.
Republic of Korea	: Not determined.
Taiwan	: All components are listed or exempted.
Turkey	: Not determined.
United States	: Not determined.

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

 Indicates information that has changed from previously issued version.

Abbreviations and acronyms : ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number

[Procedure used to derive the classification according to Regulation \(EC\) No. 1272/2008 \[CLP/GHS\]](#)

Classification	Justification
ViraPack Transfection Kit Solution 1 Eye Irrit. 2, H319	Calculation method

[Full text of abbreviated H statements](#)

SECTION 16: Other information

<p>ViraPack Transfection Kit Solution 1 H319</p>	<p>Causes serious eye irritation.</p>
<p>ViraPack Transfection Kit Solution 2 H315 H319 H335</p>	<p>Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation.</p>
<p>Virapack Transfection Kit Solution 3 H225</p>	<p>Highly flammable liquid and vapour.</p>

[Full text of classifications \[CLP/GHS\]](#)

<p>ViraPack Transfection Kit Solution 1 Eye Irrit. 2, H319</p>	<p>SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2</p>
<p>ViraPack Transfection Kit Solution 2 Eye Irrit. 2, H319 Skin Irrit. 2, H315 STOT SE 3, H335</p>	<p>SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 SKIN CORROSION/IRRITATION - Category 2 SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE (Respiratory tract irritation) - Category 3</p>
<p>Virapack Transfection Kit Solution 3 Flam. Liq. 2, H225</p>	<p>FLAMMABLE LIQUIDS - Category 2</p>

Date of issue/ Date of revision : 30/03/2017

Date of previous issue : No previous validation.

Version : 1

[Notice to reader](#)

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.